H. Lundbeck A/S (Lundbeck) today announced that pipeline developments regarding amlenetug, a novel investigational molecule for the potential treatment of Multiple System Atrophy (MSA), will be ...
Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations – MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Alterity ...
An orally administered drug to redistribute excess iron and lower cellular oxidative stress was found to slow disease ...
Parkersburg WTAP-TV on MSN
West Virginia Parkinson’s and Movement Disorder Symposium
The Mid-Ohio Valley Parkinson’s Support Group’s Parkinson’s and Movement Disorder Symposium is an educational event for those ...
Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...
Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene therapy AB-1005 delivered to the putamen in patients with multiple system atrophy ...
Research Triangle Park, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene therapy AB-1005 ...
Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler presented new analyses from the phase II double-blinded ATH434-201 trial in MSA, showing positive effects on slowing disease progression and ...
Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...
Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback